Inari Medical (NARI) said Tuesday that treatment with FlowTriever showed superiority compared with catheter-directed thrombolytics or CDT in a randomized study that enrolled 550 intermediate-risk pulmonary embolism patients.

The company said the study achieved its primary composite endpoint, with patients experiencing three times fewer clinical deteriorations and/or therapy escalations, and "significantly less" intensive care unit admission and length of stay with FlowTriever compared with CDT.

Inari shares advanced more than 10% in recent trading.

Price: 46.96, Change: +4.40, Percent Change: +10.34